ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy

Abstract Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatment with novel oral selective estrogen receptor degraders (SERDs) like elacestra...

Full description

Saved in:
Bibliographic Details
Main Authors: Konstantinos Venetis, Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli, Marianna D’Ercole, Eltjona Mane, Chiara Frascarelli, Antonio Marra, Sara Gandini, Francesco Pepe, Simone Scagnoli, Silvia Maria Rossi, Raffaella Troiano, Elena Speziale, Carmine De Angelis, Giancarlo Troncone, Umberto Malapelle, Giuseppe Perrone, Andrea Botticelli, Giuseppe Viale, Giuseppe Curigliano, Elena Guerini Rocco, Carmen Criscitiello, Nicola Fusco
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Breast Cancer Research
Subjects:
ESR1 mutations
Metastatic breast cancer (MBC)
Endocrine therapy resistance
FFPE tissue biopsy
ctDNA
CDK4/6 inhibitors
Online Access:https://doi.org/10.1186/s13058-025-02020-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02020-x

Similar Items